European health regulator recommends approval for GSK's twice-yearly asthma drug

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...

GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
Fierce Pharma

GSK’s long-acting asthma med scores in suite of CHMP drug endorsements

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

GSK Expands Use Of Urinary Tract Infection Drug For Gonorrhoea Patients

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

GSK's $4 Billion Asthma Drug Gets First-Ever Green Light in Europe

Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...
Fierce Biotech

GSK cuts the cord on Ideaya collaboration, letting go of 2 programs

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a ...

GSK gets preliminary nod for two respiratory drugs in Europe

GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines ...

GSK (GSK) Scores Win in the Form of Lung Cancer Drug’s Orphan Drug Designation

We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) ...